Who are the leading innovators in personalized cancer vaccines for the pharmaceutical industry?

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Personalized cancer vaccines is a key innovation area in precision and personalized medicine

Personalized cancer vaccines refer to vaccines that are tailored to a particular patient’s tumor and are designed to recognize and attack cancer cells. These vaccines are created by identifying the specific somatic mutations in a patient’s tumor and use this information to create a cancer mutation signature that can be used to develop a vaccine that targets the patient’s cancer cells.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 250+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of personalized cancer vaccines.

Key players in personalized cancer vaccines – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to personalized cancer vaccines

Immatics is one of the leading patent filers in personalized cancer vaccines. The biopharmaceutical company is focused on the development of T cell immunotherapies to fight against cancer. Immatics’ XPRESIDENT technology platform helps in the identification of targets for T-cell based immunotherapies and their optimization. All XPRESIDENT peptides are sourced from native tumors including primary tissues and metastatic biopsies as well as tissues derived, and as a result the therapy is considered as personalized therapy. F. Hoffmann-La Roche and BioNTech are some of the other key patent filers in personalized cancer vaccines.

In terms of application diversity, EXUMA Biotech leads the pack, while Fate Therapeutics and CRISPR Therapeutics stood in the second and third positions, respectively. By means of geographic reach, Replimune Group held the top position, followed by Immatics and Genocea Biosciences.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Precision and Personalized Medicine in Pharma.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.